Results for this period
Full year1 April 2025–31 March 2026ConsolidatedJapanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ million).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
Deliveries related to X-ray residual stress measurement systems were generally on schedule; some commissioned healthcare equipment development projects were discontinued and the start of new commissioned development projects was delayed; inquiries from major customers for optical application and special-purpose equipment systems were strong and deliveries were also generally on schedule.
Not applicable.
| Item | Details |
|---|---|
| Fiscal Period Classification | Full year |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 April 2025–31 March 2026 |
| Net Sales | ¥2,553 million (YoY +2.7%) |
| Operating profit | ¥356 million (YoY +6.2%) |
| Ordinary income | ¥396 million (YoY +12.0%) |
| Profit attributable to owners of the parent | ¥285 million (YoY -19.7%) |
| Net income per share | ¥208.90 |
| Operating Margin | 14 |
| Equity ratio | End of the current fiscal period 79.9 / End of previous period 76.8 |
| Total assets | ¥5,020 million |
| Net assets | ¥4,009 million |
| Cash flows from operating activities | ¥582 million |
| Cash flows from investing activities | ¥-597 million |
| Cash flows from financing activities | ¥-153 million |
| Cash and cash equivalents at end of period | ¥1,734 million |
| Full-year earnings forecast | Net Sales ¥2,700 million (YoY +5.8%) / Operating profit ¥400 million (YoY +12.1%) / Ordinary income ¥420 million (YoY +6.1%) / Profit attributable to owners of the parent ¥300 million (YoY +5.0%) |
| Annual Dividend Forecast | ¥110 → ¥90（-18.2%） |
| Payout ratio | 41 |
| Segment revenue | X-ray residual stress measurement systems ¥893,358 thousand (YoY +6.4%), Healthcare Equipment ¥626,936 thousand (YoY -11.8%), Optical Application and Specialized Equipment ¥1,032,855 thousand (YoY +10.4%) |
| Segment profit | X-ray residual stress measurement systems ¥347,157 thousand (YoY -4.4%), Healthcare Equipment ¥-18,182 thousand, Optical Application and Specialized Equipment ¥328,821 thousand (YoY +27.1%) |
| Regional sales | Region Japan / Current fiscal year ¥2,211,125 thousand / Previous period ¥2,215,850 thousand, Region Asia / Current fiscal year ¥172,339 thousand / Previous period ¥172,666 thousand, Region North America / Current fiscal year ¥75,707 thousand / Previous period ¥49,154 thousand, Region Europe / Current fiscal year ¥36,934 thousand / Previous period ¥19,657 thousand, Region Other / Current fiscal year ¥57,042 thousand / Previous period ¥29,220 thousand |
| Orders received and order backlog | Orders received ¥2,519,951 thousand (YoY +99.6%) / Order backlog ¥1,843,663 thousand (YoY +98.2%) |
| Depreciation and amortization | ¥92,161 thousand |
| Breakdown of extraordinary income (loss) | Extraordinary income Not disclosed / Extraordinary loss Loss on Disposal of Fixed Assets ¥0 thousand |
| Disclosure regarding the going concern assumption | Not applicable. |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate Yes / Restatement No |
| Changes in the scope of consolidation | New 0 companies (company name: —) / Excluded 0 companies (company name: —) |
| Material subsequent events | Not applicable. |
| Availability of Supplementary Financial Results Materials | No |
| Availability of Financial Results Briefing | No |
| Issued Shares at Period-End | 1,393,459 |
| Treasury Shares at Period-End | 25,399 |
| Factors Behind Changes in Business Performance | Deliveries related to X-ray residual stress measurement systems were generally on schedule; some commissioned healthcare equipment development projects were discontinued and the start of new commissioned development projects was delayed; inquiries from major customers for optical application and special-purpose equipment systems were strong and deliveries were also generally on schedule. |
Items this document does not state (3)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Deliveries related to X-ray residual stress measurement systems were generally on schedule, while inquiries from major customers for optical application and special-purpose equipment systems were strong and deliveries were also generally on schedule. In the healthcare equipment business, however, some commissioned development projects were discontinued and the start of new commissioned development projects was delayed. Overall, the Company worked to secure orders through exhibitions and academic conferences, webinars, demonstrations and sales activities.